Lianhua Qingwen combined with conventional western medicine in treatment of COVID-19: An overview of systematic reviews

Objective: Overview the systematic review/Meta analysis of Lianhua Qingwen (连花清瘟) combined with conventional western medicine in the treatment of coronavirus disease 2019 (COVID-19). Methods: Systematic reviews/Meta-analysis of Lianhua Qingwen combined with western conventional in the treatment of COVID-19 from CNKI, Wanfang, CBM, VIP, PubMed, Embase, Cochrane Library, and Web of Sciencewere search, retrieved as of October 1, 2021. Two investigators screened the literature according to the inclusion and exclusion criteria, and determined the final inclusion of the literature. AMSTAR-2 scale, GRADE system, and PRISMA statements were used to evaluate the methodological quality and GRADE the evidence quality. Results: A total of eight systematic reviews/Meta analyses were included, including six in Chinese and four in English. The quality evaluation and evidence quality classification results show that the quality of the literature and the level of evidence were low. Conclusion: The existing evidence shows that Lianhua Qingwen combined with conventional western has a good effectin the treatment of COVID-19. However, due to the low methodological quality and evidence quality level of the systematic review/Meta analysis and the low level of evidence quality, more high-quality researchs are needed to obtain high-quality research results for verification.

Blood molecular markers associated with COVID-19 immunopathology and multi-organ damage

COVID-19 is characterized by dysregulated immune responses, metabolic dysfunction and adverse effects on the function of multiple organs. To understand host responses to COVID-19 pathophysiology, we combined transcriptomics, proteomics, and metabolomics to identify molecular markers in peripheral blood and plasma samples of 66 COVID-19-infected patients experiencing a range of disease severities and 17 healthy controls. A large number of expressed genes, proteins, metabolites, and extracellular RNAs (exRNAs) exhibit strong associations with various clinical parameters. Multiple sets of tissue-specific proteins and exRNAs varied significantly in both mild and severe patients suggesting a potential impact on tissue function. Chronic activation of neutrophils, IFN-I signaling, and a high level of inflammatory cytokines were observed in patients with severe disease progression. In contrast, COVID-19-infected patients experiencing milder disease symptoms showed robust T-cell responses. Finally, we identified genes, proteins, and exRNAs as potential biomarkers that might assist in predicting the prognosis of SARS-CoV-2 infection. These data refine our understanding of the pathophysiology and clinical progress of COVID-19. SYNOPSIS image Proteomics, metabolomics and RNAseq data map immune responses in COVID-19 patients with different disease severity, revealing molecular makers associated with disease progression and alterations of tissue-specific proteins. A multi-omics profiling of the host response to SARS-CoV2 infection in 66 clinically diagnosed and laboratory confirmed COVID-19 patients and 17 uninfected controls. Significant correlations between multi-omics data and key clinical parameters. Alteration of tissue-specific proteins and exRNAs. Enhanced activation of immune responses is associated with COVID-19 pathogenesis. Biomarkers to predict COVID-19 clinical outcomes pending clinical validation as prospective marker.